ProTEC-USA Announces Expanded Medical Gown Manufacturing Capabilities

ProTEC-USA has announced the debut of a new, state of the art production work cell that will expand and enhance its capacity to produce EZDoff medical gowns for healthcare and other critical industries.

A subsidiary of Troy, Michigan-based Cadillac Products, Inc., in-house extrusion, film converting and gown manufacturing capabilities from the company’s facilities in the USA allow ProTEC-USA to serve as a strategic, domestic supply chain partner, delivering high-quality gowns with volume-level pricing.

“COVID-19 exacerbated market demands that were already growing prior to the pandemic,” said Don Lowe, Spokesperson, ProTEC-USA. “This investment from the company in upgrades and enhancements to production lines and equipment will boost our capacity in order to better meet demand.

The new, proprietary work cell was completely designed and built inhouse, addressing all the needs for quality control and optimal cost. These gowns will be available in three color options—blue, yellow or white—and will also be available with level 1, 2 or 3 compliance, based on the depth of protective needs of the user.

“EZDoff gowns are designed to not only maintain effectiveness and mitigate potential self-contamination, but also to be mindful of the manner in which the gowns are donned and doffed in sequence with other PPE,” said Lowe. “Without touching the outside surface of the EZDoff gown to remove it, the wearer is protected against consequential contamination.”

EZDoff gowns offer several features and benefits for wearers, including:

Perforated rear yoke for safe, easy doffing of medical gowns
Sleeve with thumb loop for full arm and wrist protection, simultaneous glove donning
Apron closure to maintain the user’s coolness during work performance
Compliance with all AAMI and FDA specifications and requirements

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”